Cargando…
A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12
Monoclonal antibodies represent some of the most promising molecular targeted immunotherapies. However, understanding mechanisms by which tumors evade elimination by the immune system of the host presents a significant challenge for developing effective cancer immunotherapies. The interaction of can...
Autor principal: | Klinke, David J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243044/ https://www.ncbi.nlm.nih.gov/pubmed/20843320 http://dx.doi.org/10.1186/1476-4598-9-242 |
Ejemplares similares
-
Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study
por: Klinke, David J
Publicado: (2015) -
Localized Interleukin-12 for Cancer Immunotherapy
por: Nguyen, Khue G., et al.
Publicado: (2020) -
An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer
por: Wang, Qing, et al.
Publicado: (2020) -
Interleukin 12: still a promising candidate for tumor immunotherapy?
por: Lasek, Witold, et al.
Publicado: (2014) -
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
por: Nguyen, Hong-My, et al.
Publicado: (2020)